Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.
Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget. 2019 Nov 26;10(63):6842 Authors: Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y Abstract [This corrects the article DOI: 10.18632/oncotarget.16602.]. PMID: 31827726 [PubMed - in process]
Over the past several years, a wave of new cancer immunotherapy agents referred to as immune checkpoint inhibitors (ICIs) have transformed the standard of care for patients with cancer. ICIs are most commonly used in advanced cancers with palliative intent and recently as frontline therapy for some cancers. These new agents have been shown to extend overall survival (OS) and progression free survival (PFS) in patients with lung cancer, melanoma, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, head and neck cancer, and more.
Tumor necrosis factor (TNF) inhibitors are among the most effective treatments for inflammatory bowel disease, but questions about cancer risk have kept some clinicians from prescribing them.Medscape Medical News
Patients receiving multiple, concurrent intravenous (IV) infusions often face a serious riskâthe potential for misconnected tubing lines and dosing error. âNurses check lines to make sure there are no mix-ups, unintended disconnections, or wrong doses. The consequences can be severe,â explained Elmer Vera, a registered nurse working in critical care for 18 years. âAs the treatments for ailments become more advanced, the danger associated with multiple IV infusions continue to take lives right before the very eyes of the people who are responsible for t...
CONCLUSIONS: Although pSS is associated with a higher risk of developing NHL, the risk of NHL appears to have decreased compared with that in previous studies. Our study suggests that the risk of NHL or thyroid cancer with SS is not higher than that reported in previous studies. PMID: 31969226 [PubMed - as supplied by publisher]
Anti-Tumor Necrosis Factor (aTNF) agents are among the most effective medications used to treat pediatric inflammatory bowel diseases (pIBD). Despite their effectiveness, concerns regarding an association with lymphoma limit their use in everyday practice. We sought to determine the incidence rate and absolute risk of lymphoma in pIBD patients receiving aTNF treatment using a large, geographically diverse administrative insurance claims database.
The risk of extra-colonic cancer in IBD is unclear. While thiopurines and tumour necrosis factor- α antagonists (anti-TNFs) are associated with increased risk of skin cancer and lymphoma in IBD, there is scant data on breast cancer in IBD. We evaluated the prevalence of breast cancer in IBD and investigated the role of biologics, immunomodulators, and clinical characteristics of IBD in patients with IBD and breast cancer.
AbstractManagement of lesions involving Meckel's cave can represent a challenge for neurosurgeons, because of the deep-seated location and the surrounding complex neurovascular structures. Very small lesions arising from MC are generally asymptomatic and radiological follow-up with head MRI and PET-CT is sufficient to control these lesions. In rare cases, the rapid increase in the size of lesions and the alteration of the neurologic status make early histological characterization mandatory in the plethora of lesions arising from Meckel's cave; a very small percentage is represented by central nervous system lymphomas. Prim...
Authors: Vučićević Boras V, Vidović Juras D, Aurer I, Bašić-Kinda S, Mikulić M Abstract A 40-year-old female patient was admitted to the Department of Oral Medicine due to oral ulcerations. Oral ulcerations were present on vestibular mucosa above teeth 21, 22, 25 and 26 and were 1 cm in diameter, and also around teeth 45 and 46. The patient had prolonged neutropenia due to therapy-related myelodysplastic syndrome that progressed to therapy-related acute myeloid leukemia. Initially, the patient was successfully treated with polychemotherapy for non-Hodgkin lymphoma. Unfortunately, many toxic complicatio...
Mutations resulting in increased PI3K signaling confer increased risk of B cell lymphoma, recurrent infections, poor viral control, and autoimmunity. Allogeneic HCT is curative, but the optimal approach to HCT for these patients is still evolving as experience grows. Herein, we present the clinical outcomes of 27 patients transplanted for activating PI3K mutations. Required approvals were obtained by contributing centers.Nineteen PIK3CD patients and 8 PIK3R1 patients received 22 and 10 HCTs respectively, at median age 12 years (range 2-66) at time of first HCT.